Merck + Co., Inc.

Discovery Laboratories, Inc.

Robert Segal

Thomas Hofmann

Robert J Capetola

Bertram Pitt

Mark E Johnson

Paul I Chang

Anthony Killian

Christopher Schaber

Carlos Guardia

Lawrence I Deckelbaum

Paul J Robinson

Eva J Rucinska

Polly A Beere

Duane B Snavely

Divakar Sharma

Methods and compositions to enhance mucus clearance and to treat pulmonary lung disorders such as cystic fibrosis are disclosed. The methods utilize compositions including synthetic pulmonary surfactants having one or more phospholipids and a synthetic polypeptide, administered alone or combined with hyperosmotic agents, to patients in an amount effective to enhance mucus clearance.

Pulmonary surfactant formulations and methods for promoting mucus clearance

Regimens for the therapeutic or prophylactic administration of pulmonary surfactant to infants exhibiting or at risk of developing bronchopulmonary dysplasia are disclosed.

Surfactant treatment regimen

Angiotensin II receptor antagonists are useful for decreasing QT dispersion or inhibiting the progression of QT prolongation in patients. Also disclosed is a method for monitoring the reduction in die risk of experiencing an adverse cardiac event, such as sudden cardiac death, myocardial infarction or arrhythmias, using QT dispersion in patients treated with a therapeutically effective amount of an angiotensin II antagonist.

Method for decreasing QT dispersion or inhibiting the progression of QT dispersion with an angiotensin II receptor antagonist

Angiotensin II receptor antagonists are useful in reducing and preventing mortality and sudden cardiac death in symptomatic heart failure patients. Losartan potassium has been shown to reduce mortality and sudden cardiac death in this patient population. Additionally, losartan potassium has been shown to reduce the need for hospitalization of symptomatic heart failure patients.

Method for reducing mortality with an angiotensin II antagonist

Growing community of inventors

Gwynedd Valley, PA, United States of America

Robert Segal